{"id":"ux003","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Musculoskeletal pain"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3707382","moleculeType":"Enzyme"},"_fixedAt":"2026-03-30T12:19:28.544730","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ANGPTL3 is involved in the regulation of HDL cholesterol and triglyceride metabolism. By inhibiting ANGPTL3, UX003 aims to increase the clearance of triglycerides and reduce the production of very-low-density lipoprotein (VLDL) cholesterol.","oneSentence":"UX003 is a recombinant human monoclonal antibody that targets angiopoietin-like 3 (ANGPTL3) protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:46.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"}]},"_fixedFields":["sideEffects"],"trialDetails":[{"nctId":"NCT03604835","phase":"","title":"Mucopolysaccharidosis VII Disease Monitoring Program","status":"RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2018-01-29","conditions":"Mucopolysaccharidosis VII, MPS VII, MPS 7","enrollment":50},{"nctId":"NCT03775174","phase":"","title":"Expanded Access to Mepsevii","status":"AVAILABLE","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"","conditions":"MPS VII, Mucopolysaccharidosis VII, Sly Syndrome","enrollment":""},{"nctId":"NCT02230566","phase":"PHASE3","title":"A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2014-12","conditions":"MPS 7, Sly Syndrome, Mucopolysaccharidosis","enrollment":12},{"nctId":"NCT02432144","phase":"PHASE3","title":"A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2015-11-10","conditions":"Sly Syndrome, MPS VII, Mucopolysaccharidosis","enrollment":12},{"nctId":"NCT02418455","phase":"PHASE2","title":"Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2015-07-21","conditions":"Sly Syndrome, MPS VII, Mucopolysaccharidosis","enrollment":8},{"nctId":"NCT01856218","phase":"PHASE1, PHASE2","title":"An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2013-11","conditions":"Mucopolysaccharidosis Type 7","enrollment":3},{"nctId":"NCT02097251","phase":"","title":"An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient","status":"NO_LONGER_AVAILABLE","sponsor":"Joyce Fox","startDate":"","conditions":"Mucopolysaccharidosis Type 7","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["recombinant human beta-glucuronidase","rh-β-glucuronidase","rhGUS","recombinant human beta-glucoronidase","Mepsevii ™"],"phase":"phase_3","status":"active","brandName":"UX003","genericName":"UX003","companyName":"Ultragenyx Pharmaceutical Inc","companyId":"ultragenyx-pharmaceutical-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"UX003 is a recombinant human monoclonal antibody that targets angiopoietin-like 3 (ANGPTL3) protein. Used for Hypercholesterolemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}